FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to cardiology. Sequential pharmacological test is performed and blood pressure (BP) and heart rate (HR) are measured and electrocardiogram (ECG) is analyzed. Pharmacological test is carried out in three stages. First stage involves introduction of a loading bolus of 4 mcg/kg of levosimendan for 10 minutes which is equal to 1/3 of the standard value and if BP is not less than 100 mm Hg, HR is not more than 100 beats per minute, paroxysmal atrial fibrillation (AF) and ventricular tachycardia are absent, the second stage of the test begins. Patients with BR, HR and ECG parameters that do not match the specified values are prescribed the infusion of levosimendan at the minimum supporting dosage of 0.05 mcg/kg/min. Second stage involves introduction of loading bolus of 4 mcg/kg of levosimendan for 10 minutes which is equal to 2/3 of the standard values and if BP is not less than 100 mm Hg, HR is not more than 100 beats per minute and paroxysmal atrial fibrillation and ventricular tachycardia are absent, the third stage of the test begins. Patients with BR, HR and ECG parameters that do not match the specified values are prescribed the infusion of levosimendan at the minimum supporting dosage of 0.1 mcg/kg/min. Third stage involves introduction of loading bolus of 4 mcg/kg of levosimendan for 10 minutes which is a standard recommended dose of 12 mcg/kg and if BP is not less than 100 mm Hg, HR is not more than 100 beats per minute and paroxysmal atrial fibrillation and ventricular tachycardia are absent, an optimum supporting dose of levosimendan in an amount of 0.15 mcg/kg/min for 27-34 hours is introduced until the total dose of levosimendan equalling is achieved 12.5 mg.
EFFECT: method enables higher effectiveness of treatment of acute cardiac failure ensuring considerable reduction of the hospital and remote lethality during 12 months of observation, frequency and severity of coronary insufficiency, chronic heart failure advance, rate of complications during the period of drug administration.
1 cl, 4 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATING PATIENTS WITH MYOCARDIAL INFARCTION | 2007 |
|
RU2381795C2 |
METHOD OF TREATING ACUTE MYOCARDIAL INFARCTION | 2018 |
|
RU2702146C1 |
METHOD FOR PHARMACOLOGICAL AUTONOMIC HEART BLOCK | 2014 |
|
RU2572339C1 |
METHOD FOR PREDICTION OF RISK OF VENTRICULAR TACHYCARDIA PAROXYSMS DEVELOPMENT IN PATIENTS IN FIRST DAYS OF MYOCARDIAL INFARCTION | 2017 |
|
RU2650039C1 |
WAY OF NON-INVASIVE DIFFERENTIAL DIAGNOSTICS OF MYOCARDIAL PONTICULUSES OF CORONARY ARTERIES USING METHOD OF MODIFIED PHARMACOLOGICAL STRESS-ECHOCARDIOGRAPHY | 2007 |
|
RU2360608C1 |
METHOD OF TREATING CARDIOVASCULAR PATIENTS AFTER SUFFERING ACUTE CORONARY SYNDROME AND CARDIOSURGICAL INTERVENTIONS | 2019 |
|
RU2715209C1 |
METHOD OF DIAGNOSING MYOCARDIUM ISCHEMIA IN PATIENTS WITH CARDIAC SYNDROME X | 2012 |
|
RU2502461C1 |
METHOD FOR DIAGNOSING OPENING OF THE CORONARY ARTERY IN ACUTE MYOCARDIAL INFARCTION PATIENTS | 1999 |
|
RU2189173C2 |
METHOD FOR IDENTIFICATION LONG-TERM MORTALITY RISK AND NEFTAL CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE | 2017 |
|
RU2649964C1 |
METHOD FOR STENT THROMBOSIS PREDICTION IN THE PATIENTS WITH ACUTE CORONARY SYNDROME AFTER A PERCUTANEOUS CORONARY INTERVENTION WITH A BACKGROUND OF DOUBLE ANTIPLATELET THERAPY | 2018 |
|
RU2690892C1 |
Authors
Dates
2016-11-10—Published
2015-08-27—Filed